Table 1.
Patient characteristics.
| Total analyzed (N =17) (71%) | Total nonanalyzed (N =7) (29%) | P-value | |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 9 (53) | 3 (43) | 1.00 |
| Female | 8 (47) | 4 (57) | |
| Race, n (%) | |||
| White | 0 (0) | 2 (29) | |
| African–American | 13 (76) | 4 (57) | 0.090 |
| Hispanic | 4 (24) | 1 (14) | |
| Antiretroviral chemoprophylaxis (n) | 13 | 7 | |
| Median duration, weeks (IQR) | 3.7 (3.4, 6.1) | 7.4 (4.9, 10.1) | 0.036 |
| Infant prophylactic regimen, n (%) | 0.066 | ||
| None | 4 (24) | 0 (0) | |
| Zidovudine only | 10 (59) | 4 (57) | |
| Zidovudine with nevirapine | 2 (12) | 0 (0) | |
| Zidovudine with lamivudine | 0 (0) | 1 (14) | |
| Zidovudine with lamivudine and nevirapine | 1 (6) | 0 (0) | |
| Zidovudine with lamivudine and nelfinavir | 0 (0) | 2 (29) | |
| CDC disease classification at start of HAART, n (%) | |||
| N | 13 (76) | 4 (57) | 0.17 |
| A | 2 (12) | 0 (0) | |
| B | 2 (12) | 1 (14) | |
| C | 0 (0) | 2 (29) | |
| Age at start of HAART | |||
| Median, weeks | 8.1 | 15.4 | 0.11 |
| IQR | 5.7–11.0 | 5.9–23.4 | |
| CD4+ cell count before HAART | |||
| Median, % | 34 | 35 | |
| IQR | 29–41 | 18–49 | 0.85 |
| Pre-HAART plasma HIV-1 RNA | |||
| Median (HIV-1-RNA), log10 copies/ml | 6.1 | 4.7 | 0.004 |
| IQR | 5.7–6.5 | 4.4–5.4 | |
| Nucleoside reverse transcriptase inhibitors used with lopinavir/ritonavir, n (%) | 0.36 | ||
| Zidovidune with lamivudine | 9 (53) | 3 (43) | |
| Stavudine with lamivudine | 7 (41) | 2 (29) | |
| Stavudine with abacavir | 1 (6) | 1 (14) | |
| Zidovudine with didanosine | 0 (0) | 1 (14) | |
CDC, Centers for Disease Control; IQR, interquartile range.